𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis

✍ Scribed by Christian Walter; Knut A. Grötz; Martin Kunkel; Bilal Al-Nawas


Publisher
Springer-Verlag
Year
2006
Tongue
English
Weight
115 KB
Volume
15
Category
Article
ISSN
0941-4355

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Incidence and risk factors of bisphospho
✍ Matthew R. Stumpe; Rakesh K. Chandra; Furhan Yunus; Sandeep Samant 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 2 views

## Abstract ## Background Intravenous bisphosphonate therapy has been used for treatment of benign and malignant bone diseases and has been linked to osteonecrosis of the jaws. ## Methods Records of 638 patients treated with intravenous bisphosphonates were reviewed. Drug used, number of infusio

Bisphosphonate-associated osteonecrosis
✍ Giancarlo Tirelli; Matteo Biasotto; Silvia Chiandussi; Franca Dore; Elena De Nar 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 2 views

## Abstract ## Background. An increasing number of cases of osteonecrosis of the jaws (ONJ) in patients treated with bisphosphonates has been reported in the literature. ONJ significantly affects the patients' quality of life and its management is still extremely difficult. ## Methods. A woman w

Treatment results of bisphosphonate-rela
✍ Arno Wutzl; Edwin Biedermann; Felix Wanschitz; Rudolf Seemann; Clemens Klug; Arn 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB 👁 2 views

## Abstract ## Background. Osteonecrosis of the jaws occurs after the administration of bisphosphonates. An unequivocal treatment strategy is yet to be devised. We assess the treatment of patients with bisphosphonate‐related osteonecrosis of the jaws (BRONJ). ## Methods. The investigators studie

Treatment protocols of bisphosphonate-re
✍ Athanassios Kyrgidis; Georgios Koloutsos; Konstantinos Vahtsevanos 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB 👁 2 views

We read with great interest the article by Wutzl et al, 1 reporting a well-designed prospective study for the treatment of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in a cohort of multiple myeloma, breast cancer, and other diseases in patients. The authors duly report patients' under